



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

ZOLEdronic Acid (Aclasta®), annually



Ministry of Health



Name:	File #:	Ht (cm):
Nationality:	Civil ID:	Wt (Kg):
Gender/Age:	DOB:	BSA (m²):

Approved indication(s): Androgen deprivation-induced bone loss in men with prostate cancer.
Aromatase inhibitor-induced bone loss in women with breast cancer.
Postmenopausal osteoporosis.

Central line: Available NA **Allergies:** NKA Yes, specify; _____

Parameters: Firstly, Dental clearance. CrCl > 45 ml/min

Standard Protocol:

DRUG	DOSE	INSTRUCTIONS	DAYS
ZOLEdronic Acid (Aclasta®)	5 mg	IV in 50 mL NS over 15 min.	D1
To be repeated every 12 months until intolerable toxicity.			

Treatment Description:

Cycle	DATE	Aclasta®	Physician	Consultant

Post-treatment Medications: (The recommended home medications)

Calcium and Vit D supplementation may be needed to prevent hypocalcemia.

Comments: